• Je něco špatně v tomto záznamu ?

Interactions between anti-VEGF therapy and antitumor immunity as a potential therapeutic strategy in colorectal cancer

D. Buka, J. Dvořák, I. Richter, P. Škrobánek, T. Buchler, B. Melichar

. 2019 ; 62 (3) : 127-130. [pub] 20190819

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005523

Grantová podpora
0064190 Ministerstvo Zdravotnictví Ceské Republiky

There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by VEGF on effector T cells. Bearing in mind the recent advances of combination immunotherapy, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction of these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20005523
003      
CZ-PrNML
005      
20200603081439.0
007      
ta
008      
200511s2019 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.14712/18059694.2019.129 $2 doi
035    __
$a (PubMed)31431233
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Buka, David $7 xx0197907 $u Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic
245    10
$a Interactions between anti-VEGF therapy and antitumor immunity as a potential therapeutic strategy in colorectal cancer / $c D. Buka, J. Dvořák, I. Richter, P. Škrobánek, T. Buchler, B. Melichar
504    __
$a Literatura
520    9_
$a There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The increased antitumor immunity responses seen following anti-VEGF therapy may also be associated with the inhibition of the immunosuppressive action deployed by VEGF on effector T cells. Bearing in mind the recent advances of combination immunotherapy, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appear to represent an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction of these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity.
650    _2
$a kolorektální nádory $x imunologie $x terapie $7 D015179
650    _2
$a lidé $7 D006801
650    12
$a imunoterapie $x metody $7 D007167
650    _2
$a nádorové mikroprostředí $x imunologie $7 D059016
650    _2
$a vaskulární endoteliální růstové faktory $x antagonisté a inhibitory $7 D042442
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Josef, $d 1966- $7 xx0072583 $u Department of Oncology, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Richter, Igor $7 xx0223969 $u Department of Oncology, Regional Hospital, Liberec, Czech Republic
700    1_
$a Škrobánek, Pavel $7 xx0248538 $u Department of Oncology, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Büchler, Tomáš, $d 1974- $7 xx0096851 $u Department of Oncology, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
773    0_
$w MED00010947 $t Acta Medica (Hradec Kralove) $x 1805-9694 $g Roč. 62, č. 3 (2019), s. 127-130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31431233 $y Pubmed
856    41
$u https://actamedica.lfhk.cuni.cz/media/pdf/18059694.2019.129.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 3077 $c 1072 $y p $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200602142946 $b ABA008
999    __
$a ok $b bmc $g 1530858 $s 1095578
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 62 $c 3 $d 127-130 $e 20190819 $i 1805-9694 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
GRA    __
$a 0064190 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$b NLK118 $a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace